FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1694554668> ?p ?o ?g. }

• W1694554668 abstract "The decision to approve a new drug is based on its having a satisfactory balance of benefits and risks on the basis of the information available at that time. Once a product is marketed, new information will be generated, which may have an impact on the benefit-risk profile of the product. The detailed evaluation of the new information generated through pharmacovigilance activities is important for all products to ensure their safe use. No degree of care and caution at the pre-clinical and clinical testing stages can guarantee an absolute safety when a product is marketed and prescribed in large populations with settings different from the clinical trials. Thus, a strong pharmacovigilance system is required to ensure the continuous monitoring and evaluation of the new safety data generated under the real-world conditions on the effects, side effects, contraindications, drug interactions, new indications and use in new populations of all drugs.Indian market has mostly seen the launch of only those products that have been already approved and marketed in the regulated markets of USA, Europe, Japan or other countries. For assessing the benefit-risk profile of a drug and to take appropriate corrective actions, the Indian pharmaceutical companies as well as the regulators have been depending on the experiences gained from these markets where the drug was being used for several years before introduction in India, thus bypassing the requirement to establish a strong pharmacovigilance system of their own.In recent years, many Indian companies are increasing the investment in research and development and are enhancing their capacity to develop and market new drugs with their own research efforts. Further, India is becoming a hub for clinical research activities due to its large population, high enrolment rate, and low cost. Moreover, the lag period when a drug is placed for the first time on the market in USA, Europe, Japan or somewhere else in the world, and its subsequent availability in India has decreased considerably. As a result, for such drugs the long-term safety data is not available and the time of their marketing in India.[1,2] This is clear by the fact that all the high-profile drugs that have been recently withdrawn were available in Indian market. In such cases, the Indian regulatory agencies cannot count on the experience of other markets to assess benefit-risk balance of a drug, thereby stressing the importance of developing their own adequately designed pharmacovigilance system in India. All these factors have drawn the attention of not only Drugs Controller General of India (DCGI), but also of World Health Organization (WHO), and the pharmaceutical companies toward the inadequacy of pharmacovigilance systems in India. For an effective pharmacovigilance system to be functional and efficient, all the stakeholders need to be alert and attentive through out the lifecycle of a medicinal product in the market.The office of the DCGI has been making sincere attempts for the implementation the National Pharmacovigilance Program (NPP)[3] in India. Further, the Schedule Y[4] of the Drugs and Cosmetics Act 1945 was thoroughly reviewed and amended in 2005 to include and elaborate the pharmacovigilance obligations of the companies attempting to market/develop new drugs in India.This article provides the details of the pharmacovigilance obligations of the pharmaceutical companies marketing their products in India, for generic products, for clinical trials of new chemical entity (NCE) and Indian pharmaceutical companies with pharmacovigilance headquarters in India and subsidiaries in other countries." @default.
• W1694554668 created "2016-06-24" @default.
• W1694554668 creator A5007179160 @default.
• W1694554668 date "2008-02-01" @default.
• W1694554668 modified "2023-09-23" @default.
• W1694554668 title "Pharmacovigilance obligations of the pharmaceutical companies in India." @default.
• W1694554668 cites W2050984621 @default.
• W1694554668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3038525" @default.
• W1694554668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21369406" @default.
• W1694554668 hasPublicationYear "2008" @default.
• W1694554668 type Work @default.
• W1694554668 sameAs 1694554668 @default.
• W1694554668 citedByCount "15" @default.
• W1694554668 countsByYear W16945546682012 @default.
• W1694554668 countsByYear W16945546682013 @default.
• W1694554668 countsByYear W16945546682014 @default.
• W1694554668 countsByYear W16945546682015 @default.
• W1694554668 countsByYear W16945546682016 @default.
• W1694554668 countsByYear W16945546682018 @default.
• W1694554668 crossrefType "journal-article" @default.
• W1694554668 hasAuthorship W1694554668A5007179160 @default.
• W1694554668 hasConcept C112930515 @default.
• W1694554668 hasConcept C142724271 @default.
• W1694554668 hasConcept C144133560 @default.
• W1694554668 hasConcept C17744445 @default.
• W1694554668 hasConcept C199539241 @default.
• W1694554668 hasConcept C2524010 @default.
• W1694554668 hasConcept C27548731 @default.
• W1694554668 hasConcept C2779652045 @default.
• W1694554668 hasConcept C2780035454 @default.
• W1694554668 hasConcept C33923547 @default.
• W1694554668 hasConcept C535046627 @default.
• W1694554668 hasConcept C57658597 @default.
• W1694554668 hasConcept C71924100 @default.
• W1694554668 hasConcept C90673727 @default.
• W1694554668 hasConcept C94625758 @default.
• W1694554668 hasConcept C98274493 @default.
• W1694554668 hasConceptScore W1694554668C112930515 @default.
• W1694554668 hasConceptScore W1694554668C142724271 @default.
• W1694554668 hasConceptScore W1694554668C144133560 @default.
• W1694554668 hasConceptScore W1694554668C17744445 @default.
• W1694554668 hasConceptScore W1694554668C199539241 @default.
• W1694554668 hasConceptScore W1694554668C2524010 @default.
• W1694554668 hasConceptScore W1694554668C27548731 @default.
• W1694554668 hasConceptScore W1694554668C2779652045 @default.
• W1694554668 hasConceptScore W1694554668C2780035454 @default.
• W1694554668 hasConceptScore W1694554668C33923547 @default.
• W1694554668 hasConceptScore W1694554668C535046627 @default.
• W1694554668 hasConceptScore W1694554668C57658597 @default.
• W1694554668 hasConceptScore W1694554668C71924100 @default.
• W1694554668 hasConceptScore W1694554668C90673727 @default.
• W1694554668 hasConceptScore W1694554668C94625758 @default.
• W1694554668 hasConceptScore W1694554668C98274493 @default.
• W1694554668 hasLocation W16945546681 @default.
• W1694554668 hasOpenAccess W1694554668 @default.
• W1694554668 hasPrimaryLocation W16945546681 @default.
• W1694554668 hasRelatedWork W187968587 @default.
• W1694554668 hasRelatedWork W1966857406 @default.
• W1694554668 hasRelatedWork W1967354598 @default.
• W1694554668 hasRelatedWork W1976739527 @default.
• W1694554668 hasRelatedWork W1977968435 @default.
• W1694554668 hasRelatedWork W2030790380 @default.
• W1694554668 hasRelatedWork W2050984621 @default.
• W1694554668 hasRelatedWork W2072004432 @default.
• W1694554668 hasRelatedWork W2105185941 @default.
• W1694554668 hasRelatedWork W2135506929 @default.
• W1694554668 hasRelatedWork W2528053971 @default.
• W1694554668 hasRelatedWork W2571431400 @default.
• W1694554668 hasRelatedWork W2601237759 @default.
• W1694554668 hasRelatedWork W2767214709 @default.
• W1694554668 hasRelatedWork W2806097296 @default.
• W1694554668 hasRelatedWork W2982391956 @default.
• W1694554668 hasRelatedWork W2991672895 @default.
• W1694554668 hasRelatedWork W3123126370 @default.
• W1694554668 hasRelatedWork W2181644841 @default.
• W1694554668 hasRelatedWork W2183754834 @default.
• W1694554668 isParatext "false" @default.
• W1694554668 isRetracted "false" @default.
• W1694554668 magId "1694554668" @default.
• W1694554668 workType "article" @default.